Postoperative chemotherapy relative dose intensity and overall survival in patients with colon cancer
Cancer Chemotherapy and Pharmacology · 2024
DOI: 10.1007/s00280-024-04665-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Justin C Brown und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA, 70808, USA. Justin.Brown@pbrc.edu. Hauptthemen laut MEDLINE: Colonic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Fluorouracil. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, NIH.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: Quantifying the association of chemotherapy relative dose intensity (RDI) with overall survival may enable supportive care interventions that improve chemotherapy RDI to estimate their magnitude of potential clinical benefit. METHODS: This cohort study included 533 patients with stage II-III colon cancer who initiated a planned regimen of 12 cycles of 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy. The primary exposure was chemotherapy RDI. The primary outcome was overall survival. Restricted cubic splines estimated hazard ratios (HR). RESULTS: Chemotherapy regimen RDI was associated with overall survival in an L-shaped pattern (linear P = 0.006; nonlinear P = 0.057); the risk of death was flat above 85% but increased linearly below 85%. For example, a decrease in RDI from 85 to 75% was associated with an increased risk of death [HR: 1.20 (95% CI: 1.08, 1.52)], whereas an increase in RDI from 85 to 95% was not associated with the risk of death [HR: 1.06 (95% CI: 0.82, 1.38)]. CONCLUSION: If chemotherapy RDI is considered a potential surrogate of overall survival, supportive care interventions that improve chemotherapy RDI might confer a potential clinical benefit in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA, 70808, USA. Justin.Brown@pbrc.edu.
- LSU Health Sciences Center New Orleans School of Medicine, 1901 Perdido St, New Orleans, LA, 70112, USA. Justin.Brown@pbrc.edu.
- Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, 533 Bolivar St, New Orleans, LA, 70112, USA. Justin.Brown@pbrc.edu.
- Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.
- Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA, 70808, USA.
- Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, USA.
ORCID-Profile: Justin C Brown
Förderung
- NIH HHS
- NCI NIH HHS
- NIH
Zitieren
APA
Brown, J. C., Meyerhardt, J. A., Yang, S., & Caan, B. J. (2024). Postoperative chemotherapy relative dose intensity and overall survival in patients with colon cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04665-5
Vancouver
Brown JC, Meyerhardt JA, Yang S, Caan BJ. Postoperative chemotherapy relative dose intensity and overall survival in patients with colon cancer. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04665-5
BibTeX
@article{Brown2024,
author = {Brown, Justin C and Meyerhardt, Jeffrey A and Yang, Shengping and Caan, Bette J},
title = {Postoperative chemotherapy relative dose intensity and overall survival in patients with colon cancer},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2024},
doi = {10.1007/s00280-024-04665-5}
}
EUVIMED